VectorSelect for Lentivirus
Cell Therapy Manufacturing (Lentiviral Vector)
Development/PartneringActive
Key Facts
Indication
Cell Therapy Manufacturing (Lentiviral Vector)
Phase
Development/Partnering
Status
Active
Company
About 64x Bio
64x Bio is a private, platform-based biotech company founded in 2020 and headquartered in San Francisco. The company's mission is to solve the critical manufacturing scalability challenges facing advanced therapies like gene and cell therapies through its proprietary VectorSelect™ platform. This platform combines high-throughput genetic screening and computational biology to systematically engineer production cell lines for higher yield and efficiency. 64x Bio operates a B2B business model, offering both licensed products (like its AAV Apex Suite) and custom optimization services to biopharma partners and CDMOs.
View full company profile